JP2017537629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537629A5 JP2017537629A5 JP2017529741A JP2017529741A JP2017537629A5 JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5 JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017529741 A JP2017529741 A JP 2017529741A JP 2017537629 A5 JP2017537629 A5 JP 2017537629A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- set forth
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 1158
- 230000004048 modification Effects 0.000 claims description 404
- 238000012986 modification Methods 0.000 claims description 404
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 220
- 239000000427 antigen Substances 0.000 claims description 172
- 102000036639 antigens Human genes 0.000 claims description 172
- 108091007433 antigens Proteins 0.000 claims description 172
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 229920001184 polypeptide Polymers 0.000 claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 230000009826 neoplastic cell growth Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 208000034578 Multiple myelomas Diseases 0.000 claims description 20
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 230000000139 costimulatory effect Effects 0.000 claims description 14
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 9
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101710174800 G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 101100225046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl2 gene Proteins 0.000 claims description 2
- 101100225047 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ecl3 gene Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 101150058725 ecl1 gene Proteins 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 230000004043 responsiveness Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088286P | 2014-12-05 | 2014-12-05 | |
| US62/088,286 | 2014-12-05 | ||
| PCT/US2015/064102 WO2016090312A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Division JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537629A JP2017537629A (ja) | 2017-12-21 |
| JP2017537629A5 true JP2017537629A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2019-01-17 |
| JP6919091B2 JP6919091B2 (ja) | 2021-08-18 |
Family
ID=56092565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529741A Active JP6919091B2 (ja) | 2014-12-05 | 2015-12-04 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Pending JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020198690A Withdrawn JP2021040652A (ja) | 2014-12-05 | 2020-11-30 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
| JP2023079310A Pending JP2023091037A (ja) | 2014-12-05 | 2023-05-12 | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 |
Country Status (26)
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211978T1 (hr) | 2014-12-05 | 2022-04-01 | Memorial Sloan-Kettering Cancer Center | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe |
| CN113429484A (zh) * | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| JP6925421B2 (ja) * | 2016-08-05 | 2021-08-25 | ワイ−バイオロジクス・インコーポレイテッド | プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途 |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| KR102809774B1 (ko) | 2016-12-02 | 2025-05-23 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| KR102597943B1 (ko) | 2017-01-05 | 2023-11-06 | 카 메디컬 리미티드 | Pd1-41bbl 융합 단백질 및 이의 이용 방법 |
| WO2018147245A1 (ja) * | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子 |
| AU2018258045B2 (en) | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| JP7275104B2 (ja) | 2017-08-09 | 2023-05-17 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 |
| MA49981A (fr) | 2017-08-09 | 2020-06-17 | Juno Therapeutics Inc | Procédés et compositions de préparation de cellules génétiquement modifiées |
| EP3679370A1 (en) | 2017-09-07 | 2020-07-15 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| TW201932482A (zh) | 2017-11-01 | 2019-08-16 | 美商奇諾治療有限公司 | 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸 |
| AU2018360599A1 (en) | 2017-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| WO2019090004A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| EP3710020A4 (en) | 2017-11-14 | 2021-06-23 | Memorial Sloan-Kettering Cancer Center | IL-36 SECRECTING IMMUNOREACTIVE CELLS AND RELATED USES |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| EP3720874A1 (en) | 2017-12-08 | 2020-10-14 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| WO2019113559A2 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| JP7414226B2 (ja) | 2018-03-30 | 2024-01-16 | エウレカ セラピューティクス インコーポレイテッド | Ｃｄ２２を標的とする構築物及びその使用 |
| KR20210011002A (ko) | 2018-05-16 | 2021-01-29 | 얀센 바이오테크 인코포레이티드 | 암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법 |
| MX2021000047A (es) | 2018-07-11 | 2021-05-12 | Kahr Medical Ltd | Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| BR112021002245A2 (pt) | 2018-08-09 | 2021-05-04 | Juno Therapeutics Inc | métodos para avaliar ácidos nucleicos integrados |
| KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
| JP7672340B2 (ja) * | 2018-10-19 | 2025-05-07 | メモリアル スローン ケタリング キャンサー センター | シアリルルイスａを標的とするキメラ抗原受容体およびその使用 |
| CN113227358A (zh) | 2018-10-31 | 2021-08-06 | 朱诺治疗学有限公司 | 选择并刺激细胞的方法及用于所述方法的设备 |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| JOP20210194A1 (ar) * | 2019-01-18 | 2023-01-30 | Janssen Biotech Inc | مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها |
| MX2021013223A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos. |
| MA55811A (fr) | 2019-05-01 | 2022-03-09 | Editas Medicine Inc | Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés |
| US20220249637A1 (en) | 2019-06-12 | 2022-08-11 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| BR112022008023A2 (pt) | 2019-10-30 | 2022-07-12 | Juno Therapeutics Gmbh | Dispositivos de seleção e/ou estimulação de células e métodos de uso |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4097218A1 (en) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| CA3179763A1 (en) | 2020-04-10 | 2021-10-14 | Jonathan Belk | Compounds specific to coronavirus s protein and uses thereof |
| US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| IL305950A (en) | 2021-03-17 | 2023-11-01 | Myeloid Therapeutics Inc | Engineered chimeric fusion protein compositions and methods of using them |
| EP4314280A1 (en) | 2021-03-22 | 2024-02-07 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| CN117321417A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 确定治疗性细胞组合物的效力的方法 |
| PE20242077A1 (es) * | 2021-04-07 | 2024-10-18 | Lg Chemical Ltd | Polipeptido de union a gucy2c y usos del mismo |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| WO2022247756A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| JP2024534847A (ja) | 2021-08-30 | 2024-09-26 | オリセル セラピューティクス カンパニー リミテッド | 抗ｇｐｒｃ５ｄ抗原結合タンパク質とその使用 |
| JP2024540304A (ja) | 2021-11-03 | 2024-10-31 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少 |
| CN118541399A (zh) | 2022-01-14 | 2024-08-23 | 原启生物科技(上海)有限责任公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
| JP2025504002A (ja) | 2022-01-28 | 2025-02-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物を製造する方法 |
| WO2023143537A1 (zh) | 2022-01-29 | 2023-08-03 | 恺兴生命科技(上海)有限公司 | Gprc5d抗体及其应用 |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| KR20250022800A (ko) | 2022-06-10 | 2025-02-17 | 우모자 바이오파마 인코포레이티드 | 조작된 줄기 세포 및 그의 용도 |
| WO2023250122A1 (en) * | 2022-06-24 | 2023-12-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to enpp1 polypeptides |
| EP4547269A1 (en) | 2022-06-30 | 2025-05-07 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| IL318416A (en) | 2022-08-05 | 2025-03-01 | Juno Therapeutics Inc | Chimeric antigen receptors specific for GPRC5D and BCMA |
| CN116003598B (zh) | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| AU2024214593A1 (en) | 2023-02-03 | 2025-08-07 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| EP4520346A1 (en) * | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| CN120005019A (zh) * | 2023-11-14 | 2025-05-16 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| MXPA02012434A (es) | 2000-06-16 | 2004-09-06 | Cambridge Antibody Tech | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. |
| EP1463523A4 (en) | 2001-08-20 | 2005-08-10 | Genentech Inc | PROTEIN AND NUCLEIC ACID OF THE GENDER INDUCED BY GPCR-LIKE RETINIC ACID 1 |
| AU2002367145A1 (en) | 2001-12-27 | 2003-07-15 | Sumitomo Pharmaceuticals Co., Ltd. | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20040110139A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of G protein-coupled receptor 3 expression |
| JP4898120B2 (ja) | 2002-12-20 | 2012-03-14 | アボット バイオセラピューティクス コーポレイション | Ｇｐｒ６４に対する抗体とその利用法 |
| EP1592713A2 (en) | 2003-02-13 | 2005-11-09 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| KR20060135690A (ko) * | 2003-12-10 | 2006-12-29 | 메다렉스, 인코포레이티드 | Ｉｐ―１０ 항체 및 그의 용도 |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| RU2009107277A (ru) | 2006-08-03 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ |
| US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| US7947807B2 (en) | 2007-10-15 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) |
| MX2010004482A (es) * | 2007-10-25 | 2010-07-06 | Trellis Bioscience Inc | Anticuerpos anti-proteina g vsr. |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| CA2806250C (en) | 2010-07-22 | 2020-09-22 | John W. Schrader | Cross-protective pathogen protection, methods and compositions thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) * | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| EP3881868B1 (en) * | 2013-02-15 | 2023-09-27 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| ES2645393T3 (es) * | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| CN113429484A (zh) * | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
| HRP20211978T1 (hr) | 2014-12-05 | 2022-04-01 | Memorial Sloan-Kettering Cancer Center | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| IL295295A (en) | 2015-12-04 | 2022-10-01 | Memorial Sloan Kettering Cancer Center | Antibodies against fcrl5 and methods of their use |
| CA3018382A1 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11768203B2 (en) | 2016-03-31 | 2023-09-26 | University Of Southern California | Highly sensitive and specific luciferase based reporter assay for antigen detection |
| CN112125976B (zh) | 2018-01-26 | 2022-06-03 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
-
2015
- 2015-12-04 HR HRP20211978TT patent/HRP20211978T1/hr unknown
- 2015-12-04 SI SI201531772T patent/SI3227339T1/sl unknown
- 2015-12-04 JP JP2017529741A patent/JP6919091B2/ja active Active
- 2015-12-04 AU AU2015357518A patent/AU2015357518B2/en active Active
- 2015-12-04 LT LTEPPCT/US2015/064102T patent/LT3227339T/lt unknown
- 2015-12-04 RU RU2017123551A patent/RU2762359C2/ru active
- 2015-12-04 CN CN201580075557.4A patent/CN107428829B/zh active Active
- 2015-12-04 CN CN202111126092.4A patent/CN113683711A/zh active Pending
- 2015-12-04 IL IL310130A patent/IL310130A/en unknown
- 2015-12-04 DK DK15865633.0T patent/DK3227339T3/da active
- 2015-12-04 SG SG10202007326QA patent/SG10202007326QA/en unknown
- 2015-12-04 IL IL252621A patent/IL252621B2/en unknown
- 2015-12-04 RS RS20211596A patent/RS62870B1/sr unknown
- 2015-12-04 WO PCT/US2015/064102 patent/WO2016090312A1/en not_active Application Discontinuation
- 2015-12-04 ES ES15865633T patent/ES2899779T3/es active Active
- 2015-12-04 CA CA2969864A patent/CA2969864A1/en active Pending
- 2015-12-04 EP EP21201788.3A patent/EP4015534A1/en active Pending
- 2015-12-04 MX MX2017007242A patent/MX385156B/es unknown
- 2015-12-04 PT PT158656330T patent/PT3227339T/pt unknown
- 2015-12-04 SG SG11201704547RA patent/SG11201704547RA/en unknown
- 2015-12-04 HU HUE15865633A patent/HUE057777T2/hu unknown
- 2015-12-04 EP EP15865633.0A patent/EP3227339B1/en active Active
- 2015-12-04 SM SM20220040T patent/SMT202200040T1/it unknown
- 2015-12-04 CN CN202410434671.2A patent/CN118271463A/zh active Pending
- 2015-12-04 PL PL15865633T patent/PL3227339T3/pl unknown
- 2015-12-04 MY MYPI2017000855A patent/MY192065A/en unknown
- 2015-12-04 CN CN202111119531.9A patent/CN113968912B/zh active Active
- 2015-12-04 KR KR1020177018389A patent/KR102612367B1/ko active Active
-
2017
- 2017-06-05 PH PH12017501044A patent/PH12017501044A1/en unknown
- 2017-06-05 US US15/613,800 patent/US10633426B2/en active Active
- 2017-06-05 MX MX2021008798A patent/MX2021008798A/es unknown
- 2017-06-05 SA SA517381665A patent/SA517381665B1/ar unknown
-
2020
- 2020-02-21 US US16/798,059 patent/US11820806B2/en active Active
- 2020-02-21 US US16/798,151 patent/US10906956B2/en active Active
- 2020-02-21 US US16/798,104 patent/US11866478B2/en active Active
- 2020-11-30 JP JP2020198690A patent/JP2021040652A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200052A patent/AU2022200052A1/en not_active Abandoned
- 2022-02-07 CY CY20221100105T patent/CY1125008T1/el unknown
-
2023
- 2023-05-12 JP JP2023079310A patent/JP2023091037A/ja active Pending
- 2023-11-22 US US18/517,766 patent/US20240294599A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537629A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2017537925A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2017123551A (ru) | Химерные антигенные рецепторы, нацеленные на рецептор, связанный с g-белками, и их применение | |
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| JP2018504094A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| US11951172B2 (en) | Therapeutic molecules that bind to LAG3 and PD1 | |
| CN113597433A (zh) | Gprc5d嵌合抗原受体以及表达这些受体的细胞 | |
| AU2018363291A1 (en) | Single domain antibodies that bind to CD137 | |
| JP2017524367A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2021519072A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| WO2016090337A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
| US12421292B2 (en) | Anti-DLL3 chimeric antigen receptors and uses thereof | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| JP2016520074A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP3969474A1 (en) | Binding molecules | |
| JPWO2021016585A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPWO2020081988A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2020123705A (ru) | Композиции vcar и способы применения | |
| RU2022123916A (ru) | Клетки, экспрессирующие химерные активирующие рецепторы и химерные стимулирующие рецепторы, и их применение | |
| NZ732574B2 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
| HK40001773A (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |